Original Research Article|Articles in Press, 109961

Evaluation of acceptability, safety, and continuation rates of centchroman as postabortion nonsteroidal contraceptive pill



      To evaluate acceptability, safety, and continuation rates of centchroman following abortion.

      Study design

      Prospective, observational study. Following spontaneous/induced abortion, women were offered centchroman, 30-mg tablet twice weekly for first 3 months, then once weekly with 1 year of follow-up.


      Of 120 women who opted for centchroman, continuation rate was 91% at 12 months. There was one case of user failure and one method failure and 26% had infrequent cycles.


      Centchroman is safe, effective, has good acceptance, and continuation rate post abortion with infrequent menstrual cycles as the main limiting factor for its continuation.


      Centchroman, available in Government scheme for contraception, has good acceptance and continuation rate post abortion. Its inclusion in contraceptive choices offered for postabortion contraception can go a long way in spacing of pregnancies, decreasing repeated unintended pregnancies, unsafe abortions, maternal morbidity, and mortality.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bearak J.
        • Popinchalk A.
        • Ganatra B.
        • Moller A.
        • Tuncalp O.
        • Beavin C.
        • et al.
        Unintended pregnancy and abortion by income, region and the legal status of abortion: estimates from a comprehensive model for 1990-2019.
        Lancet Glob Health. 2020; 8: E1152-E1161
        • Ali M.
        • Cleland J.
        Contraceptive discontinuation in six developing countries: a cause specific analysis.
        Int Fam Plan Perspect. 1995; 21: 92-97
        • Cotton M.
        • Stanback J.
        • Maidouka H.
        • Taylor Thomas J.T.
        • Turk T.
        Early discontinuation of contraceptive usage in Niger and the Gambia.
        Fam Plan Perspect. 1992; 18: 145-149
        • Rosenmerg M.J.
        • Waugh M.S.
        Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons.
        Am J Obstet Gynecol. 1998; 179: 577-582
        • Nair H.S.
        • Jayasimhan P.
        A prospective study of centchroman users with special reference to its contraceptive benefit.
        J Evid Based Med Healthc. 2016; 3: 5374-5380
        • Lal J.
        Clinical pharmacokinetics and interaction of centchroman—a mini review.
        Contraception. 2010; 81: 275-280
      1. Population Research Institute: News from Latin America. One Less Weapon Against the Unborn: The Abortion Pill Gets Pulled from Market; January 1 2010. Population Research Institute. 〈〉 (accessed November 23, 2017).

        • Family Planning Division: Ministry of Health and Family Welfare, Government of India
        Reference manual for oral contraceptive pills.
        Ministry of Health and Family Welfare, Government of India, New Delhi2016
        • Kabra R.
        • Allagh K.P.
        • Ali M.
        • Jayathilaka C.A.
        • Mwinga K.
        • Kiarie J.
        Scoping review to map evidence on mechanism of action, pharmacokinetics, effectiveness and side effects of centchroman as a contraceptive pill.
        BMJ Open. 2019; 9e030373
        • Puri V.
        Dhawn B.N. Results of multicentric trial of centchroman in pharmacology for health in Asia. Allied Publishers, New Delhi, India1988: P432
        • Sharma P.
        • Sharma R.
        • Yadav J.
        Centchroman a better alternative for hormonal oral contraceptive pills.
        Int J Pharma Biosci. 2011; 2: 587-592
        • World Health Organization
        Medical eligibility criteria for contraceptive use.
        5th edn. WHO, Geneva, Switzerland2015
        • Munro M.G.
        • Critchley H.O.D.
        • Fraser I.S.
        • FIGO Menstrual Disorders Committee
        The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions.
        Int J Gynecol Obstet. 2018; 143: 393-408
        • Schreiber C.A.
        • Barnhart K.
        Contraceptive effectiveness versus efficacy.
        7th edn. Yen & Jaffe's Reproductive Endocrinology, 2014
        • International Institute for Population Sciences (IIPS), ICF
        National Family Health Survey (NFHS-5), 2019-21: India.
        IIPS, Mumbai2021
        • Doke G.
        • Kamda J.
        A study of centchroman users with special reference to its contraceptive benefit.
        Int J Reprod Contracept Obstet Gynecol. 2019; 8: 4204-4207
        • Agrawal P.
        • Kushwa P.
        • Mangal B.K.
        Evaluation of safety profile of centchroman for contraceptive purpose.
        Natl J Med Allied Sci. 2016; 5: 41-44